NeuroThera expands U.S. patents for psychedelic therapies

NeuroThera expands U.S. patents for psychedelic therapies

NeuroThera Labs, in partnership with Clearmind Medicine, has broadened its U.S. patent portfolio with three new applications. These patents focus on combinations of LSD, ketamine, and ibogaine integrated with NeuroThera's proprietary PEA technology, aiming to address mental health issues such as depression and PTSD, as well as substance use and pain disorders, according to Pluang.

What the patents cover

The recent patent applications build on NeuroThera's existing intellectual property, which includes previous patents involving MDMA and PEA. The new patents reflect the company's strategy to innovate in the field of psychedelic therapies, leveraging the therapeutic potential of these compounds to develop more effective treatments.

Collaboration with Clearmind Medicine

The collaboration with Clearmind Medicine underscores a joint effort to advance safer and more effective mental health treatments. This partnership is part of a broader trend in the health sector, where companies are increasingly focusing on psychedelic compounds as potential therapeutic agents.

Why it matters

The expansion of NeuroThera's patent portfolio is significant in the context of growing interest in psychedelic therapies for mental health and substance use disorders. As the demand for innovative treatments rises, securing intellectual property rights becomes crucial for companies aiming to lead in this emerging field.

NeuroThera's strategic patent expansion highlights the evolving landscape of mental health treatment options, emphasizing the role of psychedelics in addressing complex disorders.